BridgeBio Pharma and QED Therapeutics announced the launch of the initial phase of MyAchonJourney, a new online resource to support individuals and families living with achondroplasia. The launch of MyAchonJourney marks the start of a multi-phase initiative designed to provide ongoing, evolving support tailored to the unique needs of families at every stage of their lives with achondroplasia. Developed in collaboration with members and leaders of the skeletal dysplasia community, MyAchonJourney intends to fulfill a significant need of providing education and awareness for families with achondroplasia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio reports inducement grants under Nasdaq listing rule
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- BridgeBio price target lowered to $45 from $46 at Citi
- BridgeBio reports Q2 EPS (39c), consensus ($1.04)
- BridgeBio Pharma Announces Key Executive Leadership Shuffle